BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29925657)

  • 1. Recurrent Loss of APOBEC3H Activity during Primate Evolution.
    Garcia EI; Emerman M
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
    Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
    Ooms M; Letko M; Binka M; Simon V
    PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
    Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
    J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
    Ooms M; Letko M; Simon V
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif.
    Nakashima M; Tsuzuki S; Awazu H; Hamano A; Okada A; Ode H; Maejima M; Hachiya A; Yokomaku Y; Watanabe N; Akari H; Iwatani Y
    J Mol Biol; 2017 Apr; 429(8):1262-1276. PubMed ID: 28336404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vif adaptation to human APOBEC3H haplotypes.
    Ooms M; Brayton B; Letko M; Maio SM; Pilcher CD; Hecht FM; Barbour JD; Simon V
    Cell Host Microbe; 2013 Oct; 14(4):411-21. PubMed ID: 24139399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
    OhAinle M; Kerns JA; Malik HS; Emerman M
    J Virol; 2006 Apr; 80(8):3853-62. PubMed ID: 16571802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection.
    Yoshikawa R; Izumi T; Yamada E; Nakano Y; Misawa N; Ren F; Carpenter MA; Ikeda T; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Virol; 2016 Jan; 90(1):474-85. PubMed ID: 26491161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
    Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
    J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
    Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
    PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stably expressed APOBEC3H forms a barrier for cross-species transmission of simian immunodeficiency virus of chimpanzee to humans.
    Zhang Z; Gu Q; de Manuel Montero M; Bravo IG; Marques-Bonet T; Häussinger D; Münk C
    PLoS Pathog; 2017 Dec; 13(12):e1006746. PubMed ID: 29267382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
    Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
    J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
    Zhen A; Du J; Zhou X; Xiong Y; Yu XF
    PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
    Dang Y; Siew LM; Wang X; Han Y; Lampen R; Zheng YH
    J Biol Chem; 2008 Apr; 283(17):11606-14. PubMed ID: 18299330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
    Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
    PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict.
    Compton AA; Hirsch VM; Emerman M
    Cell Host Microbe; 2012 Jan; 11(1):91-8. PubMed ID: 22264516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
    Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
    Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.